Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy defibrillator patients - insights from the German DEVICE-registry.

[1]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[2]  M. Borggrefe,et al.  Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter‐defibrillator recipients treated with single beta‐blocker or combined amiodarone , 2020, Basic & clinical pharmacology & toxicology.

[3]  H. Lan,et al.  Amiodarone: A Comprehensive Guide for Clinicians , 2020, American Journal of Cardiovascular Drugs.

[4]  M. Borggrefe,et al.  Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. , 2019, International journal of cardiology.

[5]  J. Grob,et al.  Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. , 2017, Circulation.

[6]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[7]  G. Rada,et al.  Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. , 2015, The Cochrane database of systematic reviews.

[8]  E. Aliot,et al.  Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death: The ALPHEE Study , 2011, Circulation.

[9]  C. O'connor,et al.  Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. , 2009, European heart journal.

[10]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[11]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[12]  M. Cowie,et al.  Prediction and prevention of sudden cardiac death in heart failure , 2005, Heart.

[13]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[14]  L Seipel,et al.  Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. , 1999, International journal of cardiology.

[15]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[16]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[17]  H. Greene.  The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. , 1993, The American journal of cardiology.

[18]  B. Lüderitz,et al.  Effects of chronic amiodarone therapy on defibrillation threshold. , 1992, The American journal of cardiology.

[19]  L. H. Frame.  The Effect of Chronic Oral and Acute Intravenous Amiodarone Administration on Ventricular Defibrillation Threshold Using Implanted Electrodes in Dogs , 1989, Pacing and clinical electrophysiology : PACE.